Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome

Therapeutic Drug Monitoring

Volumn 34, Issue 6, 2012, Pages 607-614

  Malm, Heli ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

malformation; neonatal; neurodevelopment; pregnancy; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE;

ADAPTATION SYNDROME; CARDIOVASCULAR MALFORMATION; CONFERENCE PAPER; DISEASE ASSOCIATION; GESTATIONAL AGE; HEART VENTRICLE SEPTUM DEFECT; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; LONG TERM CARE; LOW BIRTH WEIGHT; MATERNAL OBESITY; MECONIUM ASPIRATION; MEDLINE; NEONATAL ADAPTATION PROBLEM; NEWBORN DISEASE; OUTCOME ASSESSMENT; PERSISTENT PULMONARY HYPERTENSION; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGENY; RIGHT VENTRICULAR OUTFLOW TRACT DEFECT;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; NEUROTOXICITY SYNDROMES; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; SEROTONIN UPTAKE INHIBITORS;

EID: 84870052789     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31826d07ea     Document Type: Conference Paper

References (94)

1. Field T. Prenatal depression effects on early development: a review. Infant Behav Dev. 2011;34:1-14.
2. El Marroun H, Jaddoe VW, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry. 2012;69:706-714.
3. Li Li D, Liu L, Odouli R. Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod. 2009;24:146-153.
4. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166:557-566.
5. Mitchell AA, Gilboa SM, Werler MM, et al National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011; 205:51.e1-8.
6. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008; 198:194.
7. Nordeng H, van Gelder MM, Spigset O, et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol. 2012;32:186-194.
8. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111-120.
9. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al. First trimester use of paroxetine and congenital heart defects: a population based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88:94-100.
10. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol. 2010; 30:249-260.
11. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med. 2010; 40:1723-1733.
12. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54:242-246.
13. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-Analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010; 88:159-170.
14. Merlob P, Birk E, Sirota L, et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol. 2009;85:837-841.
15. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:B3569.
16. Wichman CL, Moore KM, Lang TR, et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc. 2009;84:23-27.
17. Diav-Citrin O, Schectman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008;66:695-705.
18. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165:749-752.
19. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol. 2008;83:68-76.
20. Alwan S, Reefhuis J, Rasmussen SA, et al; National Birth defects Prevention study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684-2692.
21. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918-926.
22. Bérard A, Ramos E, Ray E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18-27.
23. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075-1085.
24. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy. Pharmacoepidemiol Drug Saf. 2007;16: 1086-1094.
25. Källén B, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301-308.
26. Louik C, Lin AE, Werler MM, et al. First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675-2683.
27. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17:701-704.
28. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005;106: 1289-1296.
29. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol. 2005;193:2004-2009.
30. Ericson A, Källén B, Wiholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55: 503-508.
31. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609-610.
32. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-Trimester fluoxetine exposure on the newborn. Obstet Gynecol. 1997;89:713-718.
33. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
34. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-Trimester exposure to fluoxetine (Prozac). JAMA. 1993; 269:2246-2248.
35. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med. 2009;163:949-954.
36. Toh S, Mitchell AA, Louik C, et al. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol. 2009;29:555-560.
37. Oberlander TF, Warburton W, Misri S, et al. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry. 2008;192:338-343.
38. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898-906.
39. Wen SW, Yang Q, Garner P, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol. 2006;194: 961-966.
40. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
41. Suri R, Altshuler L, Hendrick V, et al. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health. 2004;7:193-200.
42. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156: 1129-1132.
43. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061.
44. Sadler TW. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod Toxicol. 2011;32:484-489.
45. Dunkel Schetter C, Tanner L. Anxiety, depression and stress in pregnancy: implications for mothers, children, research, and practice. Curr Opin Psychiatry. 2012;25:141-148.
46. Bansil P, Kuklina EV, Meikle SF, et al. Maternal and fetal outcomes among women with depression. J Womens Health (Larchmt). 2010;19:329-334.
47. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372-2383.
48. Kwon P, Lefkowitz W. Poor neonatal adaptation in term infant. Fluoxetine toxicity. Pediatr Ann. 2008;37:131-133.
49. Knoppert DC, Nimkar R, Principi T, et al. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit. 2006;28:5-7. (Pubitemid 44391684)
50. Koren G, Finkelstein Y, Matsui D, et al. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin/norepinephrine reuptake inhibitors. J Obstet Gynaecol Can. 2009;31:348-350.
51. Franssen EJ, Meijs V, Ettaher F, et al. Citalopram serum and milk levels in mother and infant during lactation. Ther Drug Monit. 2006;28:2-4. (Pubitemid 44391683)
52. Koren G. A new indication for therapeutic drug monitoring in the neonate. Ther Drug Monit. 2006;28:1. (Pubitemid 44391682)
53. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
54. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefitrisk ratio. Am J Obstet Gynecol. 2012;207:157-163.
55. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ. 2012;344:D8012.
56. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17:801-806.
57. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579-587.
58. 't Jong GW, Einarson T, Koren G, Einarson A. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. Reprod Toxicol. 2012;34:293-297.
59. Casper RC, Gilles AA, Fleisher BE, et al. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl). 2011;217:211-219.
60. Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation -Motherisk Update 2008. Can J Clin Pharmacol. 2009;16:E66-E67.
61. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
62. Lattimore KA, Donn SM, Kaciroti N, et al. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-Analysis. J Perinatol. 2005;25:595-604.
63. Galbally M, Lewis AJ, Lum J, et al. Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study. Aust N Z J Psychiatry. 2009;43:846-854.
64. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry. 2009;42:95-100.
65. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J Clin Psychopharmacol. 2008;28:334-339.
66. Haddad PM, Pal BR, Clarke P, et al. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? J Psychopharmacol. 2005;19:554-557.
67. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactinconcentrations. Arch Gen Psychiatry. 2003;60:720-726.
68. Laine K, Kytölä J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit. 2004;26:685-687.
69. Hilli J, Heikkinen T, Rontu R, et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol. 2009;19:363-370.
70. Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry. 2008;13:65-73.
71. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand. 2010:121:471-479.
72. Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry. 2012;169:134-140.
73. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol. 2011;28:19-24.
74. Hernandez-Diaz S, Van Marter LJ, Werler MM, et al. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics. 2007;120: E272-E282. (Pubitemid 47219476)
75. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2009;18:246-252.
76. Fornaro E, Li D, Pan J, et al. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med. 2007; 176:1035-1040.
77. Lim K, Sanders A, Brain U, et al. Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure. Early Hum Dev. 2012;88: 609-615.
78. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci. 2010;31:60-65.
79. Oberlander TF, Gingrich JA, Ansorge MS. Neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009;86:672-677.
80. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci. 2008;28: 199-207.
81. Ansorge MS, Zhou M, Lira A, et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science. 2004;306: 879-881.
82. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci. 2003;4: 1002-1012.
83. Smit-Rigter LA, Noorlander CW, von Oerthel L, et al. Prenatal fluoxetine exposure induces life-long serotonin 5-HT receptor-dependent cortical abnormalities and anxiety-like behaviour. Neuropharmacology. 2012; 62:865-870.
84. Holmes A, Murphy DL, Crawley JN. Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. Biol Psychiatry. 2003;54:953-959. (Pubitemid 37415031)
85. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link? Med Hypotheses. 2010;74:880-883.
86. Salisbury AL, Ponder KL, Padbury JF, et al. Fetal effects of psychoactive drugs. Clin Perinatol. 2009;36:595-619.
87. Talge NM, Neal C, Glover V; Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-Term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry. 2007;48:245-261.
88. Klinger G, Frankenthal D, Merlob P, et al. Long-Term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol. 2011;31:615-620.
89. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336: 258-262.
90. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-1895.
91. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184-191.
92. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68:1104-1112.
93. Koren G, Nordeng H. SSRIs and persistent pulmonary hypertension of the newborn. BMJ. 2012;344:D7642.
94. Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies (author reply). Obstet Gynecol. 2011;118:1420-1421.